NCT01799486View on ClinicalTrials.gov

Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial

PHASE4UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2015

Conditions
HBV-related Liver Cirrhosis
Interventions
DRUG

Telbivudine

600 mg monotherapy supplied in film-coated tablets.

DRUG

Enecavir

0.5 mg monotherapy supplied in tablets.

DRUG

Adefovir

10 mg monotherapy supplied in tablets.

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Lin Bingliang

OTHER